[go: up one dir, main page]

AR066429A1 - Derivados de imidazolopiridina y purina como inhibidores de tirosina quinasa - Google Patents

Derivados de imidazolopiridina y purina como inhibidores de tirosina quinasa

Info

Publication number
AR066429A1
AR066429A1 ARP080101879A ARP080101879A AR066429A1 AR 066429 A1 AR066429 A1 AR 066429A1 AR P080101879 A ARP080101879 A AR P080101879A AR P080101879 A ARP080101879 A AR P080101879A AR 066429 A1 AR066429 A1 AR 066429A1
Authority
AR
Argentina
Prior art keywords
carbocyclyl
heterocyclyl
case
independently selected
6alkenyl
Prior art date
Application number
ARP080101879A
Other languages
English (en)
Inventor
Hai-Jun Zhang
Audrey Davies
Tao Wang
Mei Su
Stephanos Ioannidis
Michelle Lamb
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR066429A1 publication Critical patent/AR066429A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de la formula 1 y composiciones farmacéuticas de los mismos y sus métodos de uso. Estos compuestos proveen un tratamiento para trastornos mieloproliferativos y cáncer. Reivindicacion 1: Un compuesto caracterizado porque es de Formula(1) o una sal aceptable para uso farmacéutico del mismo, en donde Q se selecciona entre N y C(R3); D se selecciona entre N y CH; R1 se selecciona entre H, -CN, C1-6alquilo, C2-6alquenilo, C2-6alquinilo, carbociclilo de 3 a 5 miembros, heterociclilode 5 miembros, -OR1a, -SR1a, -N(R1a)2, -N(R1a)C(O)R1b, -N(R1a)N(R1a)2, -NO2, -C(O)H, C(O)R1b, -C(O)2R1a , -C(O)N(R1a)2, -OC(O)N(R1a)2 -N(R1a)C(O)2R1a, -N(R1a)C(O)N(R1a)2, -OC(O)R1b, -S(O)R1b, -S(O)2R1b, -S(O)2N(R1a)2, -N(R1a)S(O)2R1b, -C(R1a)=N(R1a), y -C(R1a)=N(OR1a), en donde dichos C1-6aIquiIo, C2-6alquenilo, C2-6aIquiniIo, carbociclilo de 3 a 5 miembros, y heterociclilo de 5 miembros están opcionalmente sustituidos con uno o más R10; R1a en cada caso se selecciona en formaindependiente entre H y C1-6aIquilo, carbociclilo de 3 a 5 miembros, y heterociclilo de 5 miembros, en donde dichos C1-6alquilo, carbociclilo de 3 a 5 miembros, y heterociclilo de 5 miembros en cada caso y en forma independiente están opcionalmentesustituidos con uno o más R10; R1b en cada caso se selecciona en forma independiente entre C1-6alquilo, C2-6alquenilo, C2-6alquiniIo, carbociclilo de 3 a 5 miembros, y heterociclilo de 5 miembros, en donde dichos C1-6aIquilo, C2-6alquenilo, C2-6alquinilo, carbociclilo de 3 a 5 miembros, y heterociclilo de 5 miembros en cada caso y en forma independiente están opcionalmente sustituidos con uno o más R10; R2 se selecciona entre H, halo, -CN, C1-6alquilo, C2-6aIqueniIo, C2-6alquiniIo,carbociclilo, heterociclilo, -OR2a, -SR2a, -N(R2a)2, -N(R2a)C(O)R2b, -N(R2a)N(R2a)2, -NO2, -C(O)H, -C(O)R2b, -C(O)2R2a, -C(O)N(R2a)2, -OC(O)N(R2a)2, -N(R2a)C(O)2R2a, -N(R2a)C(O)N(R2a)2, -OC(O)R2b, -S(O)R2b, -S(O)2R2b, -S(O)2N(R2a)2, -N(R2a)S(O)2R2b,-C(R2a)=N(R2a), y C(R2a)=N(OR2a), en donde dichos C1-6alquilo, C2-6alquenilo, C2-6alquinilo, carbociclilo, y heterociclilo están opcionalmente sustituidos con uno o más R20; R2a en cada caso se selecciona en forma independiente entre H, C1-6alquilo,carbociclilo, y heterociclilo, en donde dichos C1-6alquiIo, carbociclilo, y heterociclilo en cada caso y en forma independiente están opcionalmente sustituidos con uno o más R20; R2b en cada caso se selecciona en forma independiente entre C1-6alquiIo, C2-6alquenilo, C2-6alquinilo, carbociclilo, y heterociclilo, en donde dichos C1-6alquiIo, C2-6alquenilo, C2-6alquinilo, carbociclilo, y heterociclilo en cada caso y en forma independiente están opcionalmente sustituidos con uno o más R20;R3 se selecciona entre H, halo, -CN, C1-6aIquilo, C2-6alquenilo, C2-6alquinilo, carbociclilo, heterociclilo, -OR3a, -SR3a, -N(R3a)2, -N(R3a)C(O)R3b, -N(R3a)N(R3a)2, -NO2, -C(O)H, -C(O)R3b, -C(O)2R3a, -C(O)N(R3a)2, -OC(O)N(R3a)2, -N(R3a)C(O)2R3a, -N(R3a)C(O)N(R3a)2, -OC(O)R3b, -S(O)R3b, -S(O)2R3b, -S(O)2N(R3a)2, -N(R3a)S(O)2R3b, -C(R3a)=N(R3a) y -C(R3a)=N(OR3a), en donde dichos C1-6aIquiIo, C2-6alquenilo, C2-6alquinilo, carbociclilo, y heterociclilo están opcionalmente sustituidos con uno omás R30; R3a en cada caso se selecciona en forma independiente entre H, C1-6aIquiIo, carbociclilo, y heterociclilo, en donde dichos C1-6alquiIo, carbociclilo, y heterociclilo en cada caso y en forma independiente están opcionalmente sustituidos conuno o más R30; R3b en cada caso se selecciona en forma independiente entre C1-6aIquilo, C2-6alquenilo, C2-6aIquiniIo, carbociclilo, y heterociclilo, en donde dichos C1-6aIquiIo, C2-6alquenilo, C2-6alquinilo, carbociclilo, y heterociclilo en cadacaso y en forma independiente están opcionalmente sustituidos con uno o más R30; R4 se selecciona entre H, -CN, C1-6aIquiIo, C2-6aIqueniIo, C2-6alquiniIo, carbociclilo, heterociclilo, -N(R4a)C(O)R4b, -N(R4a)N(R4a)2, -NO2, -C(O)H, -C(O)R4b, -C(O)2R4a, -C(O)N(R4a)2, -OC(O)N(R4a)2, -N(R4a)C(O)2R4a, -N(R4a)C(O)N(R4a)2, -OC(O)R4b, -S(O)R4b, -S(O)2R4b, -S(O)2N(R4a)2, -N(R4a)S(O)2R4b, -C(R4a)=N(R4a), y -C(R4a)=N(OR4a), en donde dichos C1-6aIquiIo, C2-6alquenilo, C2-6aIquiniIo, carbociclilo, yheterociclilo están opcionalmente sustituidos con uno o más R 40; R4a en cada caso se selecciona en forma independiente entre H, C1-6aIquiIo, carbociclilo, y heterociclilo, en donde dichos C1-6aIquiIo, carbociclilo, y heterociclilo en cada caso y enforma independiente están opcionalmente sustituidos con uno o más R40; R4b en cada caso se selecciona en forma independiente entre C1-6alquilo, C2-6alquenilo, C2-6alquiniIo, carbociclilo, y heterociclilo, en donde dichos C1-6alquilo, C2-6alquenilo,C2-6-5alquinilo, carbociclilo, y heterociclilo en cada caso y en forma independiente están opcionalmente sustituidos con uno o más R40; R5 se selecciona en forma independiente entre halo, -CN, C1-6alquilo, C2-6alquenilo, C2-6alquinilo, carbociclilo,heterociclilo, -OR5a, -SR5a, -N(R5a)2, -N(R5a)C(O)R5b, -N(R5a)N(R5a)2, -NO2, -C(O)H, -C(O)R5b, -C(O)2R5a, -C(O)N(R5a)2, -OC(O)N(R5a)2, -N(R5a)C(O)2R5a, -N(R6a)C(O)N(R5a)2, -OC(O)R5b, -S(O)R5b, -S(O)2R5b, -S(O)2N(R5a)2, -N(R5a)S(O)2R5b, -C(R5a)=N(R5a), y -C(R5a)=N(OR5a); R5a en cada caso se selecciona en forma independiente entre H, C1-6alquilo, carbociclilo, y heterociclilo; R5b en cada caso se selecciona en forma independiente entre C1-6aIquiIo, C2-6alquenilo, C2-6alquinilo,carbociclilo, y heterociclilo; R10 en cada caso se selecciona en forma independiente entre halo, -CN, C1-6aIquilo, C2-6aIquenilo, C2-6alquinilo, carbociclilo, heterociclilo, -OR10a, -SR10a, -N(R10a)2, -N(R10a)C(O)R10b, -N(R10a)N(R10a)2, -NO2, -C(O)H, -C(O)R10b, -C(O)2R10a, -C(O)N(R10a)2, -OC(O)N(R10a)2, -N(R10a)C(O)2R10a, -N(R10a)C(O)N(R10a)2, -OC(O)R10b, -S(O)R10b, -S(O)2R10b, -S(O)2N(R10a)2, -N(R10a)S(O)2R10b, -C(R10a)=N(R10a), y -C(R10a)=N(OR10a); R10a en cada caso se selecciona enforma independiente entre H, C1-6alquiIo, carbociclilo, y heterociclilo; R10b en cada caso se selecciona en forma independiente entre C1-6aIquilo, C2-6alquenilo, C2-6alquinilo, carbociclilo, y heterociclilo; R20 en cada caso se selecciona en formaindependiente entre halo, -CN, C1-6aIquilo, C2-6alqueniIo, C2-6alquinilo, carbociclilo, heterociclilo, -OR20a, SR20a, -N(R20a)2, -N(R20a)C(O)R20b, -N(R20a)N(R20a)2, -NO2, -C(O)H, -C(O)R20b, -C(O)2R20a, -C(O)N(R20a)2, -OC(O)N(R20a)2, -N(R20a)C(O)2R20a, -N(R20a)C(O)N(R20a)2, -OC(O)R20b, -S(O)R20b, -S(O)2R20b, -S(O)2N(R20a)2, -N(R20a)S(O)2R20b, -C(R20a)=N(R20a), y -C(R20a)=N(OR20a); R20a en cada caso se selecciona en forma independiente entre H, C1-6aIquilo, carbociclilo, yheterociclilo; R20b en cada caso se selecciona en forma independiente entre C1-6alquilo, C2-6alquenilo, C2-6aIquinilo, carbociclilo, y heterociclilo; R30 en cada caso se selecciona en forma independiente entre halo, -CN, C1-6aIquilo, C2-6alqueniIo,C2-6alquinilo, carbociclilo, heterociclilo, -OR30a, -SR30a, -N(R30a)2, -N(R30a)C(O)R30b, -N(R30a)N(R30a)2, -NO2, -C(O)H, -C(O)R30b, -C(O)2R30a, -C(O)N(R30a)2, -OC(O)N(R30a)2, -N(R30a)C(O)2R30a, -N(R30a)C(O)N(R30a2)2, -OC(O)R30b, -S(O)R30b, -S(O)2R30b, -S(O)2N(R30a)2, -N(R30a)S(O)2R30b, -C(R30a)=N(R30a), y -C(R30a)=N(OR30a); R30a en cada caso se selecciona en forma independiente entre H, C1-6aIquilo, carbociclilo, y heterociclilo; R30b en cada caso se selecciona en forma independienteentre C1-6alquilo, C2-6alquenilo, C2-6alquinilo, carbociclilo, y heterociclilo; R40 en cada caso se selecciona en forma independiente entre halo, -CN, C1-6alquilo, C2-6alquenilo, C2-6alquinilo, carbociclilo, heterociclilo, -OR40a, -SR40a, -N(R40a)2,-N(R40a)C(O)R40b, -N(R40a)N(R40b)2, -NO2, -C(O)H, -C(O)R40b, -C(O)2R40a, -C(O)N(R40a)2, -OC(O)N(R40a)2, -N(R40a)C(O)2R40a, -N(R40a)C(O)N(R40a)2, -OC(O)R40b, -S(O)R40b, -S(O)2R40b, -S(O)2N(R40a)2, -N(R40a)S(O)2R40b, -C(R40a)=N(R40a) y -C(R40a)=N(OR40a) R40a en cada caso se selecciona en forma independiente entre H, C1-6aIquilo, carbociclilo, y heterociclilo; y R40b en cada caso se selecciona en forma independiente entre C1-6aIquiIo, C2-6alquenilo, C2-6aIquiniIo, carbociclilo, yheterociclilo.
ARP080101879A 2007-05-04 2008-05-02 Derivados de imidazolopiridina y purina como inhibidores de tirosina quinasa AR066429A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91627007P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
AR066429A1 true AR066429A1 (es) 2009-08-19

Family

ID=39592016

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101879A AR066429A1 (es) 2007-05-04 2008-05-02 Derivados de imidazolopiridina y purina como inhibidores de tirosina quinasa

Country Status (24)

Country Link
US (3) US8486966B2 (es)
EP (1) EP2152705A1 (es)
JP (1) JP5415403B2 (es)
KR (1) KR101563372B1 (es)
CN (1) CN101679426A (es)
AR (1) AR066429A1 (es)
AU (1) AU2008247159B2 (es)
BR (1) BRPI0811534A2 (es)
CA (1) CA2684693C (es)
CL (1) CL2008001297A1 (es)
CO (1) CO6251294A2 (es)
EC (1) ECSP099751A (es)
IL (1) IL201691A0 (es)
MX (1) MX2009011944A (es)
MY (1) MY147890A (es)
NZ (1) NZ581633A (es)
PE (1) PE20090238A1 (es)
RU (1) RU2481348C2 (es)
SA (1) SA08290271B1 (es)
TW (1) TWI406864B (es)
UA (1) UA99459C2 (es)
UY (1) UY31065A1 (es)
WO (1) WO2008135785A1 (es)
ZA (1) ZA200907679B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
KR20100090250A (ko) * 2007-10-09 2010-08-13 메르크 파텐트 게엠베하 글루코키나제 활성체로서 유용한 피리딘 유도체
GB0725218D0 (en) * 2007-12-24 2008-02-06 Syngenta Ltd Chemical compounds
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
BR112014006840A2 (pt) 2011-09-22 2017-04-04 Pfizer derivados de pirrolopirimidina e purina
CN102952084A (zh) * 2012-11-15 2013-03-06 大连九信生物化工科技有限公司 一种4，6－二氯－2－甲硫基－5－硝基嘧啶的合成方法
CA2901427A1 (en) 2013-03-07 2014-09-12 Califia Bio, Inc. Mixed lineage kinase inhibitors and method of treatments
CN104003943A (zh) * 2014-05-06 2014-08-27 南通常佑药业科技有限公司 一种替格瑞洛中间体的制备方法
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
GB201717260D0 (en) 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021227907A1 (en) * 2020-02-25 2022-09-29 Dana-Farber Cancer Institute, Inc. Potent and selective degraders of ALK
TW202239410A (zh) 2020-12-29 2022-10-16 美商金字塔生技公司 局部醫藥組合物及方法
WO2023248151A1 (en) 2022-06-24 2023-12-28 Pyramid Biosciences, Inc. Method of treating skin field cancerization with actinic keratoses

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417402A (en) 1972-03-30 1975-12-10 Boots Co Ltd Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de) 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
US5006116A (en) 1988-12-21 1991-04-09 Kimberly-Clark Corporation Tampon with single layer powder bonded wrap
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) 1992-08-31 1999-04-13 Miguel A. Cacho Automated fluid bed process
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
CA2230896A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DK0970369T3 (da) 1997-03-27 2002-01-28 Glatt Gmbh Fremgangsmåde til overvågning og/eller styring og regulering af en granulerings-, agglomererings-, instantiserings-, coating- og tørringsproces i en fluid bed eller bevæget .....
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
US6247246B1 (en) 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
WO2000014552A1 (en) 1998-09-03 2000-03-16 Malcam Ltd. Moisture measurement device using microwaves
US6227041B1 (en) 1998-09-17 2001-05-08 Cem Corporation Method and apparatus for measuring volatile content
PL204427B1 (pl) 1998-11-10 2010-01-29 Janssen Pharmaceutica Nv Hamująca replikację wirusa HIV pochodna pirymidyny, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna
US6337338B1 (en) 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
MXPA02002559A (es) 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
AP1639A (en) 1999-09-24 2006-07-24 Janssen Pharmaceutica Nv Pharmaceutical compositions of antiviral compounds and processes for preparation.
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
ES2335265T3 (es) 1999-12-28 2010-03-24 Pharmacopeia, Inc. Inhibidores de citoquina, especialmente de tnf-alfa.
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
EP1301498A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PT1317448E (pt) 2000-09-15 2005-08-31 Vertex Pharma Compostos de pirazole uteis como inibidores de proteina-quinase
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CN100408573C (zh) 2000-12-21 2008-08-06 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
EP1423380B1 (en) 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
ATE392421T1 (de) 2001-08-03 2008-05-15 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
US6747461B2 (en) 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2006087530A (ja) * 2004-09-22 2006-04-06 Nakashima Propeller Co Ltd 橈骨遠位端骨折用内固定器具
CA2586375A1 (en) 2004-11-04 2006-05-18 Juan-Miguel Jimenez Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
JP5208516B2 (ja) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
BRPI0606793A8 (pt) * 2005-02-04 2018-03-13 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
AU2006215386B2 (en) * 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
JP2008540335A (ja) 2005-04-27 2008-11-20 アストラゼネカ・アクチエボラーグ ピラゾリル・ピリミジン誘導体の疼痛治療における使用
WO2006118231A1 (ja) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation シアノピリジン誘導体及びその医薬としての用途
EP1888561A1 (en) 2005-05-05 2008-02-20 AstraZeneca AB Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
CA2608009A1 (en) 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US20080287475A1 (en) 2005-10-28 2008-11-20 Astrazeneca Ab 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer
EP1954277B1 (en) 2005-11-03 2017-01-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2008016523A (es) 2006-06-30 2009-01-19 Astrazeneca Ab Derivados de pirimidina utiles en el tratamiento de cancer.
TW200826937A (en) 2006-11-01 2008-07-01 Astrazeneca Ab New use
TW200823196A (en) 2006-11-01 2008-06-01 Astrazeneca Ab New use
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer

Also Published As

Publication number Publication date
BRPI0811534A2 (pt) 2014-11-18
NZ581633A (en) 2012-01-12
RU2009144848A (ru) 2011-06-10
CA2684693C (en) 2015-06-23
KR20100019988A (ko) 2010-02-19
MX2009011944A (es) 2009-12-11
US20140155394A1 (en) 2014-06-05
WO2008135785A1 (en) 2008-11-13
ZA200907679B (en) 2010-07-28
CL2008001297A1 (es) 2009-01-16
AU2008247159B2 (en) 2011-11-10
RU2481348C2 (ru) 2013-05-10
JP2010526128A (ja) 2010-07-29
SA08290271B1 (ar) 2012-02-07
US20150011545A1 (en) 2015-01-08
MY147890A (en) 2013-01-31
JP5415403B2 (ja) 2014-02-12
US8486966B2 (en) 2013-07-16
KR101563372B1 (ko) 2015-10-26
PE20090238A1 (es) 2009-04-21
CA2684693A1 (en) 2008-11-13
CO6251294A2 (es) 2011-02-21
TWI406864B (zh) 2013-09-01
AU2008247159A1 (en) 2008-11-13
CN101679426A (zh) 2010-03-24
TW200902530A (en) 2009-01-16
ECSP099751A (es) 2009-12-28
US20100324040A1 (en) 2010-12-23
IL201691A0 (en) 2010-05-31
UA99459C2 (en) 2012-08-27
UY31065A1 (es) 2009-01-05
EP2152705A1 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
AR066429A1 (es) Derivados de imidazolopiridina y purina como inhibidores de tirosina quinasa
AR066147A1 (es) Pirazol-pirimidinas, composicion farmaceutica, proceso y uso en trastornos mieloproliferativos, sindrome mielodisplasico y cancer
AR073327A1 (es) Heterociclos nitrogenados y su uso como anticancerigenos
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
MX2015008971A (es) Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor.
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
AR084903A1 (es) Derivados de aminodihidrotiazina fusionada
MA38050B1 (fr) Inhibiteurs de gdf-8
CA2875877C (en) Syk inhibitors
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR070531A1 (es) Inhibidores de cinasa pim y metodos para su uso
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
PE20181272A1 (es) Heterociclilaminas como inhibidores de pi3k
SV2011003997A (es) Pirimidinas fusionadas
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
AR069899A1 (es) Compuestos quimicos derivados de pirazol-triazina
ECSP055867A (es) Derivados de pirrolopirimidina
CR20140294A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX342212B (es) Inhibidores de neprilisina.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
GEP201606507B (en) Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors
GB201201744D0 (en) Novel compounds
AR072085A1 (es) Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.

Legal Events

Date Code Title Description
FB Suspension of granting procedure